Doxazosin
| 證據等級: L5 | 預測適應症: 2 個 |
目錄
Doxazosin: From Hypertension / BPH to Migraine Disorder
One-Sentence Summary
Doxazosin is a selective α1-adrenergic receptor blocker clinically established for the treatment of hypertension and benign prostatic hyperplasia (BPH). The TxGNN model predicts it may be effective for Migraine Disorder, with 0 clinical trials and 1 publication (a 1997 expert opinion) currently supporting this direction. Evidence is very limited, and the biological plausibility is low-to-moderate.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Hypertension / Benign Prostatic Hyperplasia (pharmacological class reference; no NZ regulatory record available) |
| Predicted New Indication | Migraine Disorder |
| TxGNN Prediction Score | 99.20% |
| Evidence Level | L4 |
| New Zealand Market Status | Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Doxazosin is a selective α1-adrenergic receptor blocker. By occupying α1 receptors on vascular smooth muscle, it reduces peripheral vascular resistance — the mechanism underlying its use in hypertension and BPH. Detailed MOA data from the regulatory dataset is not currently available; the following analysis draws on established pharmacological knowledge.
The mechanistic hypothesis linking doxazosin to migraine prophylaxis rests on three pathways: (1) α1 receptors are widely distributed in cerebral vasculature, and their blockade may modulate cerebrovascular tone, which is dysregulated during migraine attacks; (2) sympathetic overactivation is thought to trigger cortical spreading depression (CSD), a key pathophysiological event in migraine — α1 blockade may attenuate this process; (3) the established first-line migraine prophylactic agents are β-blockers (e.g., propranolol), confirming that adrenergic signalling broadly plays a role in migraine pathophysiology and lending indirect biological plausibility to adrenergic blockade as a therapeutic strategy.
However, biological plausibility is assessed as low-to-moderate overall. No clinical trial has ever been registered for doxazosin in migraine. The only supporting evidence is a single 1997 expert opinion with a sample of 10 patients and a 50% discontinuation rate due to side effects. The absence of any follow-up research in nearly 30 years substantially limits confidence in this prediction. The high TxGNN score (99.20%) likely reflects the model's graph proximity between doxazosin and migraine disorder rather than independent clinical signal.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 9074296 | 1997 | Expert Opinion | Headache | Small case series (n=10) of migraine patients treated with terazosin or doxazosin in a general neurology practice; 9/10 showed decreased migraine frequency, severity, or both; 5/10 discontinued due to side effects; no serious adverse events reported |
New Zealand Market Information
Doxazosin is not currently marketed in New Zealand. No Medsafe authorizations are on record.
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The sole supporting evidence is a 1997 expert opinion with only 10 patients and a 50% discontinuation rate due to adverse effects; no clinical trials have been initiated in the nearly 30 years since publication. The drug is not marketed in New Zealand, creating a significant additional regulatory hurdle before any repurposing pathway could be pursued.
To proceed, the following is needed:
- Mechanism of action (MOA) data from DrugBank or primary pharmacology literature
- Full safety profile — key warnings, contraindications, and drug-drug interactions — sourced from the approved package insert
- At minimum, a structured retrospective case series or pilot feasibility study with pre-defined efficacy and safety endpoints
- Regulatory pathway scoping for a non-marketed drug seeking a new indication in New Zealand
- Assessment of the second TxGNN-predicted indication (Migraine with Brainstem Aura, score 99.19%, L5) — currently no evidence exists and the decision is Hold pending any primary data
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.